ArticleBMC pregnancy and childbirth2026
Does the number of abnormal values in the oral glucose tolerance test impact pregnancy outcomes?
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational diabetes mellitus (GDM) affects over 10% of pregnancies worldwide, leading to various maternal and neonatal complications. The American College of Obstetricians and Gynecologists (ACOG) recommends a two-step diagnostic approach using the Glucose Challenge Test (GCT) and the oral glucose tolerance test (OGTT), which can yield between 0 and 4 abnormal values (AbVs). The primary objective of this study was to evaluate the association between the number of AbVs in the OGTT and the risk of GDMA2 - gestational diabetes mellitus requiring pharmacological treatment (insulin or oral glucose-lowering agents) - compared with GDMA1, which is diet-controlled. Secondary outcomes included assessing the relationship between the number of AbVs and adverse maternal and neonatal outcomes, considering its impact on the course of pregnancy, delivery, maternal health, and neonatal outcomes.
methodsThis retrospective cohort study included all pregnant women who underwent OGTT between the years 2015 and 2022, and diagnosed with GDM, at our department. The study cohort was divided into four groups based on the number of AbVs in the OGTT: one AbV, two AbVs, three AbVs and four AbVs group. Maternal characteristics and pregnancy outcomes were compared between these groups.
resultsA total of 1821 women diagnosed with GDM following the diagnostic OGTT were included in the analysis. The distribution of abnormal OGTT AbVs was as follows: one AbV (36.95%), two AbVs (43.71%), three AbVs (16.09%), and four AbVs (3.24%). Presence of GDMA2 varied significantly among groups (p < 0.001), with higher occurrence correlating with increased AbVs. Maternal outcomes differed across the AbV groups in induction of labor (p < 0.001), episiotomy (p = 0.006), and maternal composite outcomes (p = 0.011). Neonatal outcomes also differed across the AbV groups, with differences in gestational age at delivery (p = 0.007) and Apgar score < 7 (p = 0.021). Logistic regression adjusted for confounders revealed that the number of AbVs (aOR 1.2, 95% CI 1.01-1.42) and maternal BMI (aOR 1.07, 95% CI 1.05-1.1) were significantly associated with GDMA2.
conclusionsAn elevated number AbVs indicates challenges in glycemic control through dietary measures alone, necessitating potential medical interventions. An increased number of AbVs in OGTT was associated with GDMA2 and induction of labor. Differences were also observed across groups in episiotomy rates and Apgar < 7, although Apgar < 7 did not show a consistent positive correlation with the number of AbVs. From the study results we can infer that OGTT serves not only as a diagnostic tool for GDM but also enables healthcare practitioners to enhance their awareness of potential adverse outcomes for both the mother and neonate through meticulous analysis of AbVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.